GDC-1261 and INR731 enter phase 1, but how do they act?
ApexOnco Front Page
Recent articles
The group is pitting its anti-CD19 T-cell engager MK-1045 head-to-head against Blincyto.
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
New pivotal trials will soon start for LaNova’s ADC and FutureGen’s MAb.
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
The company discontinues one of its two KRAS G12D degraders.
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
